Search companies

Live

OPTISCAN IMAGING LIMITED (ASX: OIL)

Health care · News and insights

OIL: $0.145 -6.45% · MC: $162M

Latest OIL announcements

Optiscan Targets US Rollout After Filing Two Human Device Applications

2026-11-17 · Health care

OIL: $0.145 -6.45% · MC: $162M

Optiscan Imaging says it filed US regulatory applications for its InForm and InVue human imaging devices in October, with clearances anticipated from October next year, subject to review. The company plans to place consoles at up to five US reference sites before expanding to its first customer accounts. Its first own-brand clinical product, InSpecta, launched in the US veterinary market in July.

Updated 2026-11-17 10:38
Share
SourcesBell Potter Healthcare Conference Presentation
Comments

Optiscan Appoints Russell Low as Clermont Board Nominee

2026-11-05 · Health care

OIL: $0.155 +3.33% · MC: $162M

Optiscan Imaging has appointed Clermont Group executive Russell Low as a non-executive director, replacing Sean Gardiner, whose resignation is effective today. Low is Clermont’s president and Singapore country head and previously chaired Vietnamese hospital operator Hoan My Medical Corporation. The appointment comes after Optiscan reported lodging US regulatory submissions for its InForm and InVue devices, which remain subject to review.

Updated 2026-11-05 15:48
Share
SourcesOptiscan Strengthens Board with Appointment of Russell Low
Comments

Optiscan Lodges Two U.S. FDA Applications, Advancing Devices Into Review

2026-10-30 · Health care

OIL: $0.155 +3.33% · MC: $162M

Optiscan says it lodged U.S. FDA applications for its InForm digital pathology and InVue precision surgery devices shortly after quarter-end, moving both into formal review; U.S. market entry remains subject to clearance. The company also signed two Mayo Clinic research agreements and launched its InSpecta veterinary device in the U.S. during the quarter.

Updated 2026-10-30 12:01
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments